Drugs that contain Duvelisib
1. Drug name - COPIKTRA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8193182 | SECURA | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
Feb, 2030
(7 years from now) | |
| USRE46621 | SECURA | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
May, 2032
(9 years from now) | |
| CN104926815A | SECURA | Some Real Chemistry, Composition And Method |
Jan, 2029
(6 years from now) | |
| CN101965335A | SECURA | Certain Chemical Entities, Compositions And Methods |
Jan, 2029
(6 years from now) | |
| CN101965336B | SECURA | Chemistry, Composition And Method |
Jan, 2029
(6 years from now) | |
| CN104926815B | SECURA | Some Real Chemistry, Composition And Method |
Jan, 2029
(6 years from now) | |
| CN101965336A | SECURA | Certain Chemical Entities, Compositions And Methods |
Jan, 2029
(6 years from now) | |
| CN101965335B | SECURA | Some Real Chemistry, Composition And Method |
Jan, 2029
(6 years from now) | |
| CN102711767B | SECURA | Some Real Chemistry, Composition And Method |
Jul, 2030
(7 years from now) | |
| CN109912599A | SECURA | Chemical Entities, Compositions And Methods |
Jul, 2030
(7 years from now) | |
| CN109912599B | SECURA | Chemical Entities, Compositions And Methods |
Jul, 2030
(7 years from now) | |
| CN106188059A | SECURA | Some Real Chemistry, Composition And Method |
Jul, 2030
(7 years from now) | |
| CN102711767A | SECURA | Certain Chemical Entities, Compositions And Method |
Jul, 2030
(7 years from now) | |
| CN106188059B | SECURA | Certain Chemical Entities, Compositions And Method |
Jul, 2030
(7 years from now) | |
| CN103648499B | SECURA | Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone |
Jan, 2032
(9 years from now) | |
| CN103648499A | SECURA | Preparation Method For Isoquinoline Ketone And Solid Form Of Isoquinoline Ketone |
Jan, 2032
(9 years from now) | |
| IN317213B | SECURA | A Compound Of Formula V-A Or V-B |
Jan, 2029
(6 years from now) | |
| IN201200943P1 | SECURA | Certain Chemical Entities, Compositions And Methods |
Jul, 2030
(7 years from now) | |
| EP2240452A1 | SECURA | 1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Derivatives As Pi3 Kinase Modulators, Their Compositions And Uses |
Jan, 2029
(6 years from now) | |
| EP2240451A4 | SECURA | Certain Chemical Entities, Compositions And Methods |
Jan, 2029
(6 years from now) | |
| EP2240452A4 | SECURA | Certain Chemical Entities, Compositions And Methods |
Jan, 2029
(6 years from now) | |
| EP2240451A1 | SECURA | Isoquinolinone Derivatives Substituted With A Purine Useful As Pi3K Inhibitors |
Jan, 2029
(6 years from now) | |
| EP3613743A1 | SECURA | Processes For The Preparation Of 1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Derivatives |
Jan, 2029
(6 years from now) | |
| EP3613743B1 | SECURA | Processes For The Preparation Of 1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Derivatives |
Jan, 2029
(6 years from now) | |
| EP2240451B1 | SECURA | Isoquinolinone Derivatives Substituted With A Purine Useful As Pi3K Inhibitors |
Jan, 2029
(6 years from now) | |
| EP2240452B1 | SECURA | 1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Derivatives As Pi3 Kinase Modulators, Their Compositions And Uses |
Jan, 2029
(6 years from now) | |
| EP3150609A1 | SECURA | Process For Preparing Certain Chemical Entities |
Jul, 2030
(7 years from now) | |
| EP3150609B1 | SECURA | Process For Preparing Certain Chemical Entities |
Jul, 2030
(7 years from now) | |
| EP2918589B1 | SECURA | Adenine Derivative As Pi3K Inhibitor |
Jul, 2030
(7 years from now) | |
| EP3441392B1 | SECURA | A Pharmaceutical Composition For Oral Administration |
Jul, 2030
(7 years from now) | |
| EP2918589A1 | SECURA | Adenine Derivative As Pi3K Inhibitor |
Jul, 2030
(7 years from now) | |
| EP3441392A1 | SECURA | A Pharmaceutical Composition For Oral Administration |
Jul, 2030
(7 years from now) | |
| EP2456444A4 | SECURA | Certain Chemical Entities, Compositions And Methods |
Jul, 2030
(7 years from now) | |
| EP2456444A1 | SECURA | Adenine Derivative As Pi3K Inhibitor |
Jul, 2030
(7 years from now) | |
| EP2456444B1 | SECURA | Adenine Derivative As Pi3K Inhibitor |
Jul, 2030
(7 years from now) | |
| EP2663309B1 | SECURA | Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones |
Jan, 2032
(9 years from now) | |
| EP3238722A1 | SECURA | Solid Forms Of Isoquinolinones |
Jan, 2032
(9 years from now) | |
| EP2663309A4 | SECURA | Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones |
Jan, 2032
(9 years from now) | |
| EP3238722B1 | SECURA | Solid Forms Of Isoquinolinones |
Jan, 2032
(9 years from now) | |
| EP2663309A1 | SECURA | Processes For Preparing Isoquinolinones And Solid Forms Of Isoquinolinones |
Jan, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216982 | SECURA | Certain chemical entities, compositions and methods |
Jan, 2029
(6 years from now) | |
| US9840505 | SECURA | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
Jan, 2032
(9 years from now) | |
Treatment: For the treatment of patients with follicular lymphoma (fl); for the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 15MG | CAPSULE;ORAL | Prescription |
| 25MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.